News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TCBP new 52 week low
$TCBP The acceptance of TC BioPharm’s amendment by the MHRA for the ACHIEVE UK trial can be seen as a bullish signal for several reasons:
1. Enhanced Trial Flexibility: The ability to increase the dose level for TCB008 and shift to an outpatient procedure may improve the trial’s efficiency and patient experience. This flexibility could potentially lead to better trial outcomes and patient adherence.
2. Operational Efficiency: Reducing the need for overnight hospital stays for patients after dosing not only improves the quality of life for participants but also eases the burden on clinical sites. This operational efficiency can accelerate the trial’s progress.
3. Positive Regulatory Feedback: Gaining regulatory acceptance for amendments suggests a positive interaction between TC BioPharm and regulatory bodies, indicating that the company is responsive and adaptable to both regulatory requirements and clinical insights.
4. Potential Impact on FDA Trial: The amendments align with the dosing levels of the Investigational New Drug (IND) application for the second cohort, which might streamline the process for the FDA trial. This proactive approach to aligning international trial standards may facilitate smoother regulatory negotiations and trial implementations in multiple jurisdictions.
5. Innovative Treatment Potential: The focus on TCB008 and its application in treating Acute Myeloid Leukemia (AML) underscores TC BioPharm’s commitment to developing innovative cancer treatments. Success in these trials could position the company as a leader in gamma-delta T cell therapies, potentially opening up significant market opportunities.
In.
TCBP new 52 week low
TCBP new 52 week low
TCBP new 52 week low
TCBP new 52 week low
Yes they are. No doubts here. IND application approval decision was due yesterday. News any day. Most likely Monday morning.
I see this board still sleeping on TCBP with IND application approval pending for AML patients who are refractory/relapse .
Article pertinent to TCBP regarding AML treatment that mentions TCBP at the end.https://www.barchart.com/story/news/21369384/why-the-relapsedrefractory-acute-myeloid-leukemia-market-is-expected-to-witness-revolutionary-developments
Big Boys in control #WeHaveThePower $TCBP
#WeHaveThePower $TCBP
SONIC BOOM >> $TCBP <<
Strong volume .. tons of loading. $TCBP
Nice consolidation today $TCBP will fly into next week and beyond!! #LongAndStrong
|
Followers
|
13
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
508
|
|
Created
|
03/02/22
|
Type
|
Free
|
| Moderators | |||
